Key facts
- It has raised $93.6M; the latest was Later Stage VC ($13.6M) in Feb 2026.
- Notable investors include Baidu Ventures, EDBI, SEEDS Capital, Polaris Partners, The Invus Group — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Engine Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Engine Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Engine Biosciences
Developer of a network biomedicine platform designed to map and decipher complex biological networks for effective and efficient drug discovery. The company's integrated computational and experimental platform generates data on gene networks, analyzes interactions across millions to billions of genes, and produces biological insights validated in well-controlled experiments, enabling drug discovery scientists and developers to decipher genetic codes and identify disease-driving errors.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2014
- Employees
- 32
- Website
- enginebio.com/
- Ownership
- Privately Held (backing)
Engine Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Engine Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Engine Biosciences in its N-PORT filings yet. We sweep new filings monthly.